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Abstract
During cancer progression, specific genomic aberrations arise that can determine the scope of the disease and can be used
as predictive or prognostic markers. The detection of specific gene amplifications or deletions in single blood-borne or
disseminated tumour cells that may give rise to the development of metastases is of great clinical interest but technically
challenging. In this study, we present a method for quantitative high-resolution genomic analysis of single cells. Cells were
isolated under permanent microscopic control followed by high-fidelity whole genome amplification and subsequent
analyses by fine tiling array-CGH and qPCR. The assay was applied to single breast cancer cells to analyze the chromosomal
region centred by the therapeutical relevant EGFR gene. This method allows precise quantitative analysis of copy number
variations in single cell diagnostics.
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Introduction
During cancer formation and progression, cell populations with
distinct genetic aberrations arise that represent unique clinical entities
harbouring specific therapeutic targets [1,2]. A prominent example is
the gene locus of the epidermal growth factor receptor (EGFR), which
is a key player in tumor biology and an important target for
individualized cancer therapy. The DNA copy numbers for this single
locus significantly determine the phenotype of cancer cells and are
indicators for patient’s response to chemotherapy or radiotherapy [3].
Antibodies and small molecule inhibitors have been developed
impairing EGFR tyrosine kinase activity in various tumor types [1–3].
Most tumors can be completely removed by surgery and are
therefore unavailable for repeated sampling to monitor either
treatment response or treatment-induced changes in genomic
aberrations or disease progression, respectively. Recently, these
crucial processes can be assessed by the detection of blood-borne
cancer cells or disseminated tumor cells (DTCs) in bone marrow,
as prominent homing organ and major site of overt metastases in
cancer patients. The molecular analysis of these cells may reveal
unique information to tailor therapies preventing metastatic
progression [4,5].
Therefore, we developed an approach for a reliable high-
resolution quantitative genetic analysis of isolated single tumor cells
on the example of the EGFR gene. After enrichment, cells were
isolated by micromanipulation and subsequent linear whole genome
amplification was performed. Evaluation of this procedure has been
done by fine-tiling array-CGH and quantitative PCR in order to
accurately determine amplitude and extension of the EGFR
amplicon in single tumor cells.
Results
Micromanipulation and whole genome amplification of
single cells
The human mammary adenocarcinoma cell line MDA-MB-468
was selected as suitable model for method evaluation, since it
harbors an EGFR amplification and shows strong EGFR
overexpression as well as displays a stemness/committed progen-
itor cell phenotype [6,7]. However the level of amplification varies
between cells. For whole genome amplification (WGA), non-fixed
or slightly fixed cells were collected from the glass surface using a
micromanipulator equipped with a capillary designed to our
specific requirements. Cells were transferred in an aqueous
surrounding onto a C18-silane-coated glass stick carrying a spot
of dried complete cell lysis buffer (see online methods). The cell
lysate on the glass stick was directly transferred into a reaction tube
already prepared with the sample buffer for WGA to avoid any
loss of genomic material. The procedure is based on multi-
displacement amplification by the use of random hexamers and
the proofreading DNA polymerase Phi29 to ensure linear
amplification [8]. A single cell yielded in 2.04–2.96 mg PCR-
amplifiable DNA (average: 2.42 mg, SD 0.26), which is superior to
the results previously described [9].
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WGA of one single cell including the EGFR locus of approximately
4.5 MB were validated with microsatellite PCR. Microsatellite loci
have been adapted from Tidow et al. [10] and detailed
information is provided as supplementary information (Table
S1, S2). All microsatellite loci could be verified.
Description of the EGFR amplicon in single cells by fine
tiling array CGH
To control for linear amplification of the DNA sequences by
WGA and to investigate the structure of the EGFR amplicon, we
analyzed the region harboring the EGFR gene by a high-resolution
two-color fine-tiling array-CGH (Roche NimbleGen Inc., Madi-
son, WI, USA). The custom-designed oligonucleotide arrays with
15 bp median probe spacing cover a genomic sequence of
approximately 4.7 Mbp on chromosome 7p11.2, including the
EGFR gene itself, and two reference regions on chromosome 2 and
chromosome 10 of about 200 kbp length each [11]. In general,
these reference regions show only minor genomic aberrations. A
correlation plot comparing the signal intensities between the
hybridization from the amplified DNA obtained from one single
cell compared to genomic DNA obtained from 500 cells indicates
the reliability of the preparation, pre-amplification steps and array
hybridization (figure 1c).
Data analyses of cell lines carrying EGFR amplifications (MDA-
MB-468, A431, and BT20) revealed an amplicon on chromosome
7 that consists of a main part containing the entire EGFR gene.
This central element is extended in the telomeric direction with a
sharp border at the end (figure 1 a, b), which indicated that the
amplicon is initiated at a distinct DNA sequence. From single cell
analysis of MDA-MB-468 cells displaying different EGFR copy
numbers, the precise amplicon borders were calculated by the
smoothing function of the Quantsmooth algorithm [12]. A further
extension of the amplicon was found in MDA-MB-468 cells with
the highest copy number gain (32 copies), showing an additional
sequence extension on the centromeric site (figure 1b). The data
were validated by quantitative SYBR-green PCR using LINE1
repetitive sequences as an intrinsic constant copy control [13]
(Table S3 and S4). This approach allows reproducible absolute
DNA quantification in a single cell, which has not been reported
so far.
Description of the EGFR amplicon in single cells by qPCR
Our next goal was the development of a reliable assay that can
assist therapy decisions in clinical routine. The results of the fine-
tiling array-CGH have shown that the amplified regions differ in
length dependent on the level of amplification of the whole region
(figure 1), but in all cases, the EGFR gene itself is included. Based
on the copy number levels determined by fine-tiling array analysis,
we standardized absolute qPCR measurements for the EGFR
exons 4, 7, 9, 15, and 21 and the non-coding 59-sequence of the
amplicon at position 54,485,000 in a SYBR green assay to
accurately describe EGFR amplifications in one single cell
(TableS5). The PCR efficiency ranged between 98.07% and
99.02% (average: 98.78%, SD 0.36). All assays showed consistent
results as presented in figure 2a. In clinical routine, where a simple
and robust assay is desirable, the reduction of these PCR reactions
to exon 7 and 9 and at the 59-end-sequence is sufficient.
Genomic heterogeneity in blood-borne cancer cells and
DTC populations from individual patients
To investigate, whether this integral approach developed and
optimized by using MDA-MB-468 cells, as model is also suitable
for the analyses of patient samples, we tested blood samples and
bone marrow samples of patients with metastatic breast cancer.
Cells were prepared as previously described [5,14]. Cytokeratin
and EpCAM antibodies are used as markers for the detection of
blood-borne or disseminated cancer cells [5]. We isolated several
single cells, stained with the antibody A45B/B3, from different
patient samples by micromanipulation and performed WGA as
described above. The WGA yielded in 1.96–2.84 mg DNA
(average: 2.36 mg, SD 0.25), which is comparable with the yield
obtained from single cultured cells. WGA was controlled by the
use of LINE1 DNA [13], which yielded in a mean of 330 ng
(range 3 ng–621 ng, SD 211) amplification product and allowed
the precise calculation of the PCR-amplifiable DNA in each
sample. From every patient sample, we analyzed four cells by
qPCR for exons 7 and 9 (figure 2) and the 59-end-sequence (data
not shown). The values of the EGFR measurements in non-tumor
cells have a median of about 0.9 in both qPCR assays, which is
expected to reflect the normal copy number of 2 (box plots of
figure 2c). Compared to these values, one third of the cells showed
a high EGFR amplification of at least 5-fold (p,0.0001), and about
25% of the samples showed a gain between 2- and 3-fold
(p,0.001). The detailed results for the single cells are shown in
figure 2c and 2d. One sample did not show consistence between
the measurements in exons 7 and 9. For this sample, we performed
additional qPCR measurements on exons 4, 15, and 21, which all
show a normal copy number for the respective locus. No single
tumor cell presented with a ‘‘normal’’ gene copy number. Cancer
cells without amplification of the EGFR gene showed low copy
number values (,0.7). These values are rather expected to be
caused by variation in the WGA procedure than by technical
artifacts of the qPCR, since the calculated starting amount of DNA
from most samples applied to the qPCR reaction (.40 pg) is
sufficient for reliable measurements and is in the range of the
calibration curves as shown for LINE1 intrinsic control (figure 2d).
Discussion
The aim of the study was the development of a protocol that
allows the quantitative genomic analysis of single tumor cells.
Primary tumor cells of epithelial origin are heterogeneous. It has
been speculated that only a small proportion of these cells show
specific ‘‘stem cell – like’’ features and may give rise to metastases
(reviewed in [15]). These cells may be characterized by specific
genomic aberrations that would provide them with growth
advantages and a more aggressive phenotype. This view is
supported by data from EGFR inhibitor studies as such, EGFR-
mutated adenocarcinoma represent a unique clinical entity
necessitating molecular diagnostics for therapy guidance [1].
Moreover, the generation of therapy resistant cell clones harboring
additional EGFR mutations or amplifications during therapy as
well as the overexpression and amplification of EGFR regulating
genes, e.g. ERFI1, have already been reported [2,16] Therefore,
the genomic investigation of single tumor cells that either reside in
the blood or in the bone marrow may help to improve predictive
molecular diagnostics. Particular in breast cancer, EGFR signaling
seems to be upregulated in basal-like tumors (triple-negatives),
especially in cells with stem cell like features [6,7,17,18].
Preliminary experimental data exist that benetits from EGFR
targeted therapy by cetuximab or laptinib are related to EGFR
amplification level [6].
Several research groups have investigated the possibility to
analyze a single tumor cell on the molecular level [19,20]. It has
been shown that the genome wide detection of aberrations by the
use of BAC arrays is possible in leucocytes and cell line cells [21].
Quantitative Genomic Analysis of Single Cells
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between the primary and systemic disease [19] in esophageal
cancer patients, which strikingly shows the need of the analysis of
single disseminated tumor cells.
In our study, we chose the MDA-MB-468 cell line model to
develop the protocol because of different stable EGFR amplifica-
tion levels in different clones of this cell line. By this, these cells
somehow mimic the heterogeneous in vivo situation and serve as a
well balanced control for the determination of gene copy levels.
We can show that the amplified DNA obtained from a single cell is
of sufficient quality to be used in a high-resolution fine-tiling array
analysis. The profiles of single cells show more background, but
compared to profiles from genomic DNA of the cell population the
same amplicon borders can be clearly identified. Genome wide
arrayCGH analysis gives an excellent overview about the genome
wide aberrations within a single cell, but the quantification of the
genomic changes is limited. A qPCR approach cannot be used to
screen for new aberrations, but enables us to quantify known,
potentially clinical relevant amplification and deletions. By the use
of the qPCR technique, differences in gene copy number could be
Figure 1. Fine-tiling array-CGH analyses. a: Array-CGH plots of genomic DNA of different breast carcinoma cell lines with different EGFR gene
copy numbers. b: Array-CGH plots of WGA amplified DNA from 500 MDA-MB-468 or single MDA-MB-468 cells (purchased at ATCC), respectively. The
region of the EGFR gene is depicted in green. c: Correlation plot of the signal intensities after array hybridization comparing the signals of the DNA
from one single MDA-MB-468 cell to the signals obtained from the DNA isolated from 500 MDA-MB-468 cells. Spots depicted in yellow represent the
signals outside the amplicon region, whereas spots indicated by the blue color represent the signals obtained by the amplicon region on
chromosome 7.
doi:10.1371/journal.pone.0026362.g001
Quantitative Genomic Analysis of Single Cells
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e26362clearly distinguished as well on the level of genomic DNA of a pool
of cells as on the amplified DNA obtained from one single cell. We
could show that cells obtained from an individual patient are
heterogeneous concerning their EGFR gene amplification. The
analysis of only one or two cells per blood sample can therefore
lead to results that may not reflect the true clinical situation.
Analysis of as many cells as possible is essential to identify those
cells that may not be targeted by a specific therapy due to the
heterogeneity of the cell population. This finding, if confirmed in a
larger cohort of samples, could provide new insights in the biology
of metastasis and may help to explain failure of targeted therapies
in a significant proportion of patients.
The use of a quantitative PCR assay displays a robust and cost-
effective method that can be established under routine conditions.
Compared to the use of fine-tiling-microarrays, which are more
cost intensive and less robust concerning the interpretation of the
data, this methods could potentially be used in clinical routine for
the molecular investigation of single cells. This method for the first
time displays a straightforward approach to quantify the DNA
amount of a specific genomic region from one single cell.
By this, we present a reliable method for the absolute
quantitative determination of gene copies in single cancer cells
isolated from peripheral blood or bone marrow of cancer patients.
This method may not be limited to investigate the biology of
disseminating tumor cells, but may also become a new tool for the
assessment of single cell genomics with wide applicability in many
areas of experimental research. Moreover, future clinical applica-
tions can be envisaged. Beyond the investigation of the EGFR
gene, our method can be adapted to assess other molecular targets
(e.g. HER2 [21]), and to analyze cancer cells in other cytological
samples, where the low percentage of tumor cells limits the
genomic analyses by current methods.
Materials and Methods
Ethics Statement
From patients who provided blood samples, written informed
consent has been obtained. From bone marrow samples collected
after autopsy, written approval was given by the family members.
The use of medical records, blood and bone marrow was approved
by the ethics committee of the Medical Board Hamburg (reference
number #190504).
Cell Lines and Culturing
The breast cancer cell lines MDA-MB-468, BT-20, and MCF-7
as well as the carcinoma cell line A431 were obtained from the
American Type Culture Collection (ATCC) and cultured in
DMEM with 5% heat-inactivated fetal calf serum at 5% CO2.
Figure 2. Quantitative PCR. a: Quantitative PCR assays for different EGFR exons in MDA-MB-468 clones b: Calibration curves of the qPCR assays for
the LINE-1 control and EGFR exons 7 and 9, which indicate that amplification efficiencies of the control as well as sample DNA are similar. c, d: Results
of the qPCR analysis of exon 7 and 9 in single tumor cells from cancer patients. c: Boxplots of qPCR measurements of 10 non-tumourous cells from 3
different patients. The median of the values measured in non-tumour cells is about 0.9 (horizontal line in boxes). Values above 95% confidence limits
1.377 and 1.679 are considered to be gain of exon 7 and 9, respectively. The single black dots represent the values measured in tumor cells from
patient samples, according to the table given in d.
doi:10.1371/journal.pone.0026362.g002
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transfer to slides for single cell picking.
Immunocytochemistry
Cells were incubated for 45 minutes with the primary antibody
A45B/B3 (Micromet, Munich, Germany), followed by awashing step
and a 30 minutes incubation with a rabbit-anti-mouse bridging
antibody (Z0259, Dako, Glostrup, Denmark). Detection has been
performed with the monoclonal mouse-APAAP complex (Dako,
Glostrup, Denmark) and BCIP/NBT as chromogenic substrate




Hamburg-Eppendorf, Germany. Archival bone marrow samples on
cytospins were used. From patients who provided blood samples,
written informed consent has been obtained. These samples were
obtained from patients undergoing autopsy and of which the family
members had given written approval to take bone marrow samples
for research purposes. This procedure has been approved by the
local ethical committee. From patients who provided blood samples,
written informed consent has been obtained.
Enrichment procedure for blood-borne cancer cells and
DTC
Bone marrow samples and peripheral blood samples have been
processed by a Ficoll-density gradient to enrich mononuclear cells
and possibly epithelial tumor cells as previously described [12].
Shortly, bone marrow samples were obtained from the upper iliac
crest by needle aspiration and stored in heparin-treated tubes.
Mononuclear cells including tumor cells were separated by Ficoll-
Hypaque density-gradient centrifugation with a density of
1.077 g/ml. 7610
5 cells were cytospun onto glass slides, dried at
room temperature and stored at 280uC.
Transfer of single cells
1. Silanisation of glass sticks. The glass sticks with a
diameter of 1.9–2.3 mm were rinsed for one hour in 85uCi na
solution of 10% Neodisher Laboclean FT (Dr. Weigert, Hamburg,
Germany). HPLC-clean water was used for all dilution and washing
steps. After drying, the sticks were swayed in H2SO4 (98%, Merck,
Darmstadt, Germany) for one hour at room temperature and rinsed
in water. Sticks were allowed to dry for 15 minutes at 110uCa n d
subsequently swayed in 0.5% octadecyltrichlorsilane in octane
fraction (Fluka, Erlangen, Germany) for two hours. After
incubation in 96% ethanol for one hour, residues of ethanol and
silanewereremovedbyrinsingwithwaterthoroughlyandvigorously.
Sticks can be stored dry and dark for up to eight weeks.
2. Lysis buffer. The lysis buffer is composed of 0.25% N-
lauroyl sarcosine, 2 M guanidinium thiocyanate, 0.01 M sodium
citrate pH 7.0, and 1% dimethylsulfoxide in HPLC-clean water.
The buffer was sterilized by filtration through a 0.2 mm PES filter
(VWR, Darmstadt, Germany) and stored at 220uC until use.
3. Stick preparation. Before use, DTT was added to the lysis
buffer at a final concentration of 60 mM. The complete lysis buffer
was diluted 1:10 with HPLC-clean water. To one end of each glass
stick, 0.2 ml of complete lysis buffer was applied and allowed to dry at
room temperature until complete dryness. The remaining salts now
form the so-called ‘Lysospot’.
4. Single cell picking. Subsequently, cells were collected by
the use of a micromanipulator: The microinjector Celltram Vario
and micromanipulator TransferMan NKII (Eppendorf Instruments,
Hamburg, Germany) were equipped with a custom-designed, flexible
capillary customTip type III with an inner diameter of 40 mma n da
bevelled end (45u), developed in close collaboration with Eppendorf
Instruments. Cells were transferred from the glass slide under visual
control by a nuclear fluorescent DAPI-staining to ensure that whole
nuclei were captured. To prevent loss of material during transfer and
cell lysis, cells were placed directly out of the capillary on the silane-
coated glass stick carrying the Lysospot. Due to the silane coating,
DNA binding to the glass will be prevented. Furthermore, the salts of
the Lysospot are concentrated to a very small area because of the
changes in surface tension due to the coating. The complete Lysospot
becomes activated by resolution due to the aqueous surrounding
during the transfer of the manipulated cell. The cell-containing glass
stick was transferred into a 200 ml PCR reaction tube containing 9 ml
of sample buffer of the Genomiphi V2 amplification kit (GE
Healthcare Europe, Freiburg, Germany) and transferred to 280uC
for 15 minutes. After thawing, 0.1 ml protease solution (Qiagen,
Hilden, Germany) was added, followed by an incubation step of
15 minutes at 50uC for protein digestion and an additional
incubation step of 15 minutes at 75uC for enzyme deactivation.
Whole Genome Amplification
Whole genome amplification was performed with the Genomiphi
V2 kit (GE Healthcare Europe, Freiburg, Germany) according to the
manufacturer’s protocol with the following modifications: The glass
stick remains in the reaction tube during amplification. The
amplification reaction was allowed to run for 150 minutes at 30uC
in a total volume of 20 ml. The WGA product was cleaned up with
NucleoSEQ spin columns (Macherey-Nagel, Du ¨ren, Germany) and
DNA concentrations were measured by the Nanodrop1000 (Peqlab,
Erlangen, Germany).
Microsatellite Detection
The allele status of the polymorphic repeats was investigated by
PCR amplification followed by separation on either a 2% agarose gel
or capillary electrophoresis. The reactions were performed in a total
volume of 10 ml under the conditions given below (Table S1) on a
Mastercycler gradient (Eppendorf Instruments, Hamburg, Ger-
many). The annealing temperature was adapted according to the
primers used as shown in Table S2. The separation was performed
using a four-color laser induced fluorescence capillary electrophoresis
system (AbiPrism 3130; Applied Biosystems, Wilmington, GE, USA)
utilizing GeneScan Standard ROX-500 for fragment length
evaluation. Evaluation was performed using Genemapper v2.03
evaluation software (Applied Biosystems, Wilmington, DE, USA).
Fine Tiling Array Analysis
The fine tiling array was designed by Nimblegen (Roche
NimbleGen Inc., Madison, WI) as described before [22] according
to our custom parameters (Table S6). Bases that are part of repetitive
elements have been removed from being considered for probe design.
Furthermore, the selected probes were not allowed to contain
ambiguous nucleotide codes. Additional criteria were: Annealing
temperature of 76uC, probe length between 50–75 bp, the probe was
allowed to only match once in the whole genome according to
Human genome assembly March 2006 (hg18), http://genome.ucsc.
edu (Table S6), and the probes ideally started with an offset of 15 bp.
With these specifications, about 395.000 probes can be spotted on
one array. The borders of the amplicons for the different MDA-MB-
468 cell clones were calculated by the smoothing function of the
Quantsmooth algorithm [12] and validated afterwards by quantita-
tive real-time PCR. For this purpose, a total amount of 53 SYBR
green assays were designed flanking the calculated start- and
endpoints sharing the same specifications. The assays were designed
Quantitative Genomic Analysis of Single Cells
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ensure specific quantification. Chromosome 2 and chromosome 10
were used as stable reference regions according to Naylor et al. [11]. If
necessary, the calculated start- and endpoints were corrected based
upon the array CGH plot and the qPCR results.
Quantitative RT-PCR
The quantification of the average gene copy number of EGFR
was performed using specific primers targeting singular sequences
of 50–150 bps within different exons of the EGFR gene as given in
Table S3. The PCR-reactions were performed on a Mastercycler
epgradientS Realplex4 under the conditions given in Table S4in a
total volume of 15 ml. Each sample was measured in triplicate. A
separate calibration curve was generated for each as say in each
run using leukocyte DNA from the same patient ranging from 10–
0.15 ng per reaction. DNA concentrations were normalized
referring to the constant copy number reference LINE1 [13].
Melting analyses were performed after each run to verify singular
product amplification.
EGFR gene copy numbers have been determined by calculating
the ratio between the DNA amount in the EGFR region divided by
the DNA amount in the reference region. A normal, diploid gene
copy number is ideally reflected by 1 (2n/2n), three copies of the
EGFR gene would be expected around 1.5 (3n/2n). To calculate
the cut-off for calling a sample gained, 95% confidence limits of
the reference values were used (  x xz2s). All measurements above
the upper limit were considered an EGFR gene copy number gain.
Supporting Information
Table S1 PCR protocol of the microsatellite PCR.
(PDF)
Table S2 Overview of the sequences of the microsatel-
lite primers.
(PDF)
Table S3 PCR primer pairs for the qPCR of the EGFR
gene.
(PDF)
Table S4 PCR protocol for the EGFR-qPCR.
(PDF)
Table S5 PCR primer pairs on chromosome 7.
(PDF)
Table S6 Contigs for array design.
(PDF)
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